Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience

Detalles Bibliográficos
Autores principales: Tefferi, Ayalew, Gangat, Naseema, Shah, Mithun, Alkhateeb, Hassan, Patnaik, Mrinal S., Al-Kali, Aref, Elliott, Michelle A., Hogan, William J., Litzow, Mark R., Hook, Christopher C., Mangaonkar, Abhishek, Viswanatha, David, Chen, Dong, Pardanani, Animesh, Ketterling, Rhett P., Begna, Kebede H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521235/
https://www.ncbi.nlm.nih.gov/pubmed/35734931
http://dx.doi.org/10.3324/haematol.2022.281045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521235/
https://www.ncbi.nlm.nih.gov/pubmed/35734931
http://dx.doi.org/10.3324/haematol.2022.281045

Ejemplares similares